News

Enlarge image

PolicyGermanyEU

Papers don’t tell the whole story

09.10.2013 - According to a new study, clinical trial outcomes are more complete in unpublished reports than in publicly available information.

Publicly available sources of information that report findings from clinical trials provide much less information on patient-relevant outcomes than unpublished reports, states a study published by German researchers. The results of the study by Beate Wieseler and colleagues from the Institute for Quality and Efficiency in Health Care (IQWIG) in Cologne found that the publicly available information contained less information about both the benefits and potential harms of an intervention than the unpublished report. Their findings highlight the importance of recent initiatives, such as the AllTrials initiative that aims to make clinical trial outcome data publicly available, in order to provide complete and transparent information to help patients and clinicians reach decisions about clinical care.

In the study, the researchers compared the information available in clinical study reports, which are detailed but usually unpublished accounts of clinical trials, to publicly available sources, including journal publications and registry reports. They found that unpublished reports included complete information for 86% of the patient-relevant outcomes, whereas the combined publicly available sources provided complete information for only 39% of the outcomes. Although the trials included in this study may not be representative of all trials, the findings support a draft policy released in June 2013 by the European Medicines Agency calling for the routine publication of complete clinical trial data.

The authors say: "Our findings show that a substantial amount of information on patient-relevant outcomes required for unbiased trial evaluation is missing from the public record. [Clinical study reports] should be made publicly available as they may substantially influence conclusions concerning the actual position of an individual drug in a therapeutic area."

The study is just another piece in the ongoing debate on transparency of clinical trials set to be implemented in the new EU clinical trials regulation. The pharma industry has stated its will to share clinical data of approved drugs but has also pointed out that it would be essential to exclude any use or misuse of personal data, i.e. when it comes to trials on orphan drugs. In May, the General Court of the European Union ordered the EMA not to provide any raw data on pivotal clinical trials of EU-approved drugs to competitors of originator drugs' developers.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-04/papers-dont-tell-the-whole-story.html

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

European UnionUKEU

24.06.2016 After the British people voted in favour of leaving the European Union, the industry is grappling with the profound impact this will likely have. Representatives from biotech industry, research and policits have expressed their concerns and hopes on the upcoming Brexit.

Investment FundUKIrelandEULuxembourg

24.06.2016 UK investment vehicle Malin has secured another €70m to invest in innovation and research across the European life sciences. The European Investment Bank will provide a debt facility over a period of seven years.

ImmunotherapyFranceEU

22.06.2016 TxCell has jumped on its option for a licensing agreement with the Weizmann Institute of Science’s tech transfer arm after it was granted a far-reaching patent for redirected, genetically engineered T regulatory cells by the EPO.

Clinical TrialsUK

21.06.2016 Circassia suffered a severe blow when its cat allergy immunotherapy failed to outcompete the placebo in a Phase III trial. The company’s shares, listed in London, plunged to a third of its previous value.

R&DSwitzerlandUK

16.06.2016 With support from the Medicines for Malaria Venture and Gates Foundation, Novartis will tackle resistant malaria with a new compound.

FinancingEUNetherlands

14.06.2016 European specialist investment firm Gilde Healthcare has closed its €250m fund for later stage and growth capital in medtech, digital health and therapeutics. The oversubscribed fund will invest in both Europe and North America.

AwardEUPortugalGermanyDenmarkFrance

09.06.2016 Exceptional inventors from all over Europe have been honoured with the European Inventor Award 2016. With the award, the European Patent Office recognises the achievements of inventors from Denmark, France, Germany, the Netherlands, the UK and the US.

Personalised medicineUK

08.06.2016 Finding a treatment for depression that is well-tolerated and effective is difficult and time-consuming. UK scientists have now developed a blood test to predict whether common antidepressants will work in a patient.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • PAION (D)2.02 EUR15.43%
  • PLETHORA (UK)3.38 GBP12.67%
  • GW PHARMACEUTICALS (UK)566.50 GBP11.96%

FLOP

  • THERAMETRICS (CH)0.03 CHF-25.00%
  • ALMIRALL (E)11.36 EUR-22.98%
  • OXFORD BIOMEDICA (UK)3.90 GBP-15.22%

TOP

  • IMMUPHARMA (UK)32.00 GBP12.3%
  • MAGFORCE (D)5.05 EUR11.0%
  • CYTOS (CH)0.31 CHF10.7%

FLOP

  • SARTORIUS (D)66.00 EUR-73.4%
  • CIRCASSIA LIMITED (L)82.25 GBP-69.1%
  • VALNEVA (F)2.00 EUR-39.4%

TOP

  • KARO BIO (S)24.60 SEK1657.1%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)10.98 EUR493.5%

FLOP

  • BB BIOTECH (D)39.20 EUR-84.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.42 SEK-78.4%
  • EVOCUTIS (UK)0.05 GBP-77.3%

No liability assumed, Date: 28.06.2016